P25942 (TNR5_HUMAN) Homo sapiens (Human)
Tumor necrosis factor receptor superfamily member 5 UniProtKBInterProSTRINGInteractive Modelling
Available Structures
12 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
Crystal structure of human CD40/TNFRSF5 in complex with the anti-CD40 DARPin protein |
Heteromer | 1×NA; | ||||
Assess | ||||||
STRUCTURE OF THE EXTRACELLULAR DOMAIN OF THE CD40 IN COMPLEX WITH 3H56-5 DAB |
Heteromer | 3×SO4; | ||||
Assess | ||||||
Structure of the extracellular domain of the CD40 in complex with 3H56-5 DAB |
Heteromer | 1×K; | ||||
Assess | ||||||
Crystal structure of CD40/ABBV-323 FAB complex |
Heteromer | 2×SO4; | ||||
Assess | ||||||
Crystal structure of the CD40 and CD154 (CD40L) complex |
Heteromer P29965; | 3×NAG; | ||||
Assess | ||||||
Complex of Human CD40 Ectodomain with Lob 7.4 Fab |
Heteromer | |||||
Assess | ||||||
Crystal Structure of CD40 complexed to FAB516 |
Heteromer | 2×SO4; | ||||
Assess | ||||||
Structure of the extracellular domain of the CD40 in complex with CHI220 FAB |
Heteromer | 2×SO4; | ||||
Assess | ||||||
MOLECULAR BASIS FOR CD40 SIGNALING MEDIATED BY TRAF3 |
Heteromer Q13114; | |||||
Assess | ||||||
TRAF6-CD40 Complex |
Heteromer Q9Y4K3; | |||||
Assess | ||||||
STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A 17-RESIDUE CD40 PEPTIDE |
Heteromer Q12933; | |||||
Assess | ||||||
STRUCTURE OF TNF RECEPTOR ASSOCIATED FACTOR 2 IN COMPLEX WITH A 5-RESIDUE CD40 PEPTIDE |
Heteromer Q12933; | |||||
Assess |
3 SWISS-MODEL models
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
7p3i.1.A | monomer | 0.75 | 100.00 | |||
Assess | ||||||
6pe8.2.C | monomer | 0.70 | 100.00 | |||
Assess | ||||||
6a3v.12.B | monomer | 0.56 | 28.57 | |||
Assess |
1 SWISS-MODEL model built on isoform sequence
Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
---|---|---|---|---|---|---|
Isoform 2 | 3qd6.2.E | monomer | 0.72 | 87.65 | ||
Assess |